Maxim Group analyst Jason McCarthy initiated coverage with a Buy rating on Inmune Bio Inc (INMB) today and set a price target of $13. The company’s shares closed yesterday at $7.73.
McCarthy observed:
“We are initiating coverage of $13 price target. INmune Bio is a clinical-stage immunotherapy company with three drug programs focused on harnessing the innate immune system to treat cancers and neurodegenerative diseases: INB03, XPro1595, and INKmune.”
According to TipRanks.com, McCarthy is a 1-star analyst with an average return of -0.3% and a 36.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Inovio Pharmaceuticals, and Vertex Pharmaceuticals.
Inmune Bio Inc has an analyst consensus of Moderate Buy, with a price target consensus of $13.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9 and a one-year low of $7. Currently, Inmune Bio Inc has an average volume of 12.62K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inmune Bio, Inc. is a clinical stage biotechnology company, which develops immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer. Its products include INKMUNE and INB03. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.
